Efficacy of taurine in the treatment of stress angina in patients with postinfarction cardiosclerosis

Introduction. There are reports of the effectiveness of taurine in patients with cardiovascular diseases. A wide range of this drug action due to its regulatory effect on various types of metabolism. However, there is no enough information about the possibility of taurine use in the treatment of patients with postinfarction cardiosclerosis (PIC).
Goal is to study the mechanisms of action and clinical efficacy of taurine in the treatment of patients with stable angina after myocardial infarctio.
Material and methods. 95 patients with PIC and exertional angina II and III functional class, which were randomized into 2 groups: the main group — 48 patients (65.8±7.2 years) to whom taurine was added to standard therapy (Dibikor, PIKPHARMA Russia, 750 mg/day); comparison group — 47 patients (63.6±6.9 years) who received standard therapy and placebo. The duration of treatment is 3 months, the duration of observation is 6 months. Evaluated the dynamics of clinical, instrumental and laboratory characteristics.
Results. It was found that the addition of taurine to basic therapy contributes to the treatment effectiveness of patients with PIC who have not undergone myocardial revascularization, which is manifested by significant improvements in indicators: subjective status (decreased fatigue, complaints of palpitations, dyspnea, frequency of strokes), echocardiographic parameters (an increase in the ejection fraction), bathmotropic and chronotropic functions of the myocardium (decrease in the number of ventricular and supraventricular extrasystoles, normalizing the variability of heart rate), lipid profile. It has been established that the use of taurine in the complex treatment of patients with PIC is safe and not accompanied by side effects.
Conclusion. Taurine is advisable to include in the complex treatment of patients with angina pectoris who have had a myocardial infarction in order to improve the myocardial inotropic function, enhance the antiarrhythmic and lipid-lowering effects of basic therapy. The recommended dose of taurine is 750 mg per day for at least 3 months.

1. Bkaily G., Jazzar A., Normand A., Simon Y., Al-Khoury J., Jacques D. Taurine and cardiac disease: state of the art and perspectives. Can. J. Physiol. Pharmacol. 2020;98(2):67–73.

2. Manovickaya A.V. Metabolic therapy in patients with metabolic syndrome. Poliklinika. 2012;2(1):25–28. (in Russian)

3. Belikova J., Lizogub V., Kuzminets A., Lavrenchuk I. Normalization of heart rate variability with taurine and meldonium complex in post-infarction patients with type 2 diabetes mellitus. J. Med. Life. 2019;12(3):290–5. doi: 10.25122/jml-2019-0052.

4. Ito T., Murakami S., Schaffer S.W. Taurine-conjugated metabolites in hearts. Adv. Exp. Med. Biol. 2019;1155:523–9. doi: 10.1007/978-981-13-8023-5_48.

5. Guryeva I.V., Svetlova O.V. Possibilities of metabolic therapy in the treatment of micro-and macrovascular complications of diabetes mellitus: The role of taurine. Endokrinologiya: novosti, mneniya, obuchenie. 2019;8:2:42–9. (in Russian)

6. Basalay O.N., Radkovets A.Yu., Bushma M.I. Taurine: metabolism regulator and drug. Medicinskie novosti. 2017;5:3–7. (in Russian)

7. Averin Е.Е. Experience of taurine use at the stage of rehabilitation of patients after cardiac surgery. Zhurnal serdechnaya nedostatochnost’. 2014;4(85):224–31. (in Russian)

8. Schaffer S., Kim H.W. Effects and mechanisms of taurine as a therapeutic agent. Biomol. Ther. (Seoul). 2018;26(3):225–41. doi: 10.4062/biomolther.2017.251.

9. Dallak M. A synergistic protective effect of selenium and taurine against experimentally induced myocardial infarction in rats. Arch. Physiol. Biochem. 2017;123(5):344–55. doi: 10.1080/13813455.2017.1347687.

10. Statsenko M.E., Turkina S.V., Tyschenko I.A., Gorbacheva E.E. Pathogenetic rationale for the inclusion of taurine in the treatment of patients with type 2 diabetes. Consilium Medicum. 2017;19:36–42. (in Russian)

11. Teplova N.V., Abduragimov S.A., Volov N.A., Sofrina S.L., Benev skaya M.A. Taurine in the treatment of patients with chronic heart failure. Terapiya. 2017;8(18):18–25. (in Russian)

12. Erlepesova P.M., Maksudova M.Kh., Mukhiddinova N.Z. The study of the membrane-protective efficacy of taurine in a clinical setting. Biologiya i integrativnaya medicina. 2017;2:34–41. (in Russian)

13. Metelka R. Heart rate variability — current diagnosis of the cardiac autonomic neuropathy. A review. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub. 2014;158;327–38. doi: 10.5507/bp.2014.025.